

# Harshal Abhyankar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9626125/publications.pdf>

Version: 2024-02-01

20  
papers

1,099  
citations

933447

10  
h-index

1281871

11  
g-index

20  
all docs

20  
docs citations

20  
times ranked

1427  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of the <i>BRAF</i> <sup>V600E</sup> mutation in Greek adults with Langerhans cell histiocytosis. <i>Pediatric Hematology and Oncology</i> , 2022, 39, 540-548.	0.8	2
2	Overcoming T-cell exhaustion in LCH: PD-1 blockade and targeted MAPK inhibition are synergistic in a mouse model of LCH. <i>Blood</i> , 2021, 137, 1777-1791.	1.4	25
3	BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology. <i>Nature Medicine</i> , 2021, 27, 851-861.	30.7	38
4	Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+CD207+ cells. <i>Blood Advances</i> , 2020, 4, 87-99.	5.2	25
5	Blocking MAPK Activation and Immune Checkpoints Reverse Immune Dysfunction and Reduce Disease in a Mouse Model of LCH. <i>Blood</i> , 2019, 134, 3602-3602.	1.4	0
6	Comprehensive Cell Specific Transcriptome Profiling of a Pediatric Hodgkin Lymphoma Cohort. <i>Blood</i> , 2019, 134, 2773-2773.	1.4	0
7	CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. <i>Cancer</i> , 2018, 124, 2607-2620.	4.1	73
8	Inherited Genetic Risk Factors and Langerhans Cell Histiocytosis Relapse Events. <i>Blood</i> , 2018, 132, 4278-4278.	1.4	0
9	Whole Exome Analysis Reveals Key Genomic Differences between Sporadic and Endemic Pediatric Burkitt Lymphoma. <i>Blood</i> , 2018, 132, 4117-4117.	1.4	0
10	A genome-wide association study of LCH identifies a variant in SMAD6 associated with susceptibility. <i>Blood</i> , 2017, 130, 2229-2232.	1.4	15
11	Activating <i>MAPK1</i> ( <i>ERK2</i> ) mutation in an aggressive case of disseminated juvenile xanthogranuloma. <i>Oncotarget</i> , 2017, 8, 46065-46070.	1.8	24
12	Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis. <i>Blood</i> , 2016, 128, 2533-2537.	1.4	122
13	Clonal, Exhausted and Activated Infiltrating T Lymphocytes in Langerhans Cell Histiocytosis Lesions. <i>Blood</i> , 2016, 128, 3708-3708.	1.4	0
14	Inflammatory Plasma Proteins Predict Disease Severity and Response to Therapy in Patients with LCH. <i>Blood</i> , 2015, 126, 4072-4072.	1.4	0
15	A Genome-Wide Assessment of Inherited Genetic Variants and the Risk of Langerhans Cell Histiocytosis. <i>Blood</i> , 2015, 126, 4059-4059.	1.4	0
16	<i>BRAF</i> -V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. <i>Journal of Experimental Medicine</i> , 2014, 211, 669-683.	8.5	346
17	Differentiating Skin-Limited and Multisystem Langerhans Cell Histiocytosis. <i>Journal of Pediatrics</i> , 2014, 165, 990-996.	1.8	77
18	Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. <i>Blood</i> , 2014, 124, 3007-3015.	1.4	352

#	ARTICLE	IF	CITATIONS
19	A "non-fratricidal" CD28- T Cell Receptor That Targets Survivin Expressed By Hematological Malignancies. Blood, 2013, 122, 141-141.	1.4	0
20	Plasma Biomarker Profiling In Langerhans Cell Histiocytosis: Risk-Stratifying The Inflammatory Storm. Blood, 2013, 122, 2854-2854.	1.4	0